Evercore upgrades Doximity, says guidance looks conservative

Evercore ISI upgraded Doximity (DOCS) to Outperform with a $70 price target, citing the digital health platform's conservative guidance and potential for significant upside. The firm projects Doximity's core Pharma business, bolstered by GLP-1 drug spending, and growing point-of-care products will drive fiscal 2026 revenue to approximately $630 million and adjusted EBITDA to over $365 million, exceeding consensus. Evercore highlights the company's strong operating leverage and recurring revenue profile as justification for its premium valuation, despite potential regulatory risks to pharma advertising.

Analysis

Evercore ISI has upgraded Doximity (DOCS) to Outperform with a $70 price target, based on the assessment that the company's full-year guidance is overly cautious. The firm's bullish thesis is supported by several factors, including the stability of the core Pharma business, which is expected to be bolstered by an estimated $60 million contribution from GLP-1 drug advertising in fiscal 2026. Additionally, Doximity's point-of-care and formulary products, which nearly doubled in revenue in fiscal 2025, are projected to continue their growth, potentially reaching over $140 million in fiscal 2026. Evercore's revenue forecast of approximately $630 million for the next fiscal year aligns with the high end of management's guidance, with potential for at least 5% upside if spending trends remain stable. Crucially, the analysis highlights Doximity's high operating leverage, where modest revenue outperformance could translate into significant earnings growth, with adjusted EBITDA potentially exceeding $365 million, well above the consensus estimate of $340 million. While acknowledging the stock's premium valuation, Evercore justifies it by pointing to strong margins and a recurring revenue profile, though it also notes regulatory risks to pharma ad spending as a factor to monitor.

Key Decisions for Investors

• Given the conviction that Doximity's guidance is conservative, investors could view this upgrade as a signal of potential upside, with Evercore's estimates for revenue and EBITDA significantly exceeding current market consensus.
• Investors should closely monitor the growth rates in Doximity's point-of-care and formulary product lines, as well as any management commentary on pharmaceutical spending trends, particularly related to GLP-1 drugs, as these are key catalysts for the projected outperformance.
• While the outlook is positive, it is important to factor in the noted regulatory risks that could affect the pharmaceutical advertising sector, although a potential industry shift toward digital advertising could present a long-term tailwind for Doximity.